School of Medicine, Deakin University, Geelong, VIC 3216, Australia.
Institute for Mental and Physical Health and Clinical Translation, Deakin University, Geelong, VIC 3216, Australia.
Int J Mol Sci. 2024 Oct 11;25(20):10968. doi: 10.3390/ijms252010968.
B cell lymphoma 6 (BCL6) is a conserved multi-domain protein that functions principally as a transcriptional repressor. This protein regulates many pivotal aspects of immune cell development and function. BCL6 is critical for germinal center (GC) formation and the development of high-affinity antibodies, with key roles in the generation and function of GC B cells, follicular helper T (Tfh) cells, follicular regulatory T (Tfr) cells, and various immune memory cells. BCL6 also controls macrophage production and function as well as performing a myriad of additional roles outside of the immune system. Many of these regulatory functions are conserved throughout evolution. The gene is also important in human oncology, particularly in diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL), but also extending to many in other cancers, including a unique role in resistance to a variety of therapies, which collectively make BCL6 inhibitors highly sought-after.
B 细胞淋巴瘤 6(BCL6)是一种保守的多结构域蛋白,主要作为转录抑制因子发挥作用。该蛋白调节免疫细胞发育和功能的许多关键方面。BCL6 对于生发中心(GC)的形成和高亲和力抗体的产生至关重要,在 GC B 细胞、滤泡辅助 T(Tfh)细胞、滤泡调节 T(Tfr)细胞和各种免疫记忆细胞的产生和功能中发挥关键作用。BCL6 还控制巨噬细胞的产生和功能,并在免疫系统之外发挥多种其他作用。这些调节功能在进化过程中大多是保守的。该基因在人类肿瘤学中也很重要,特别是在弥漫性大 B 细胞淋巴瘤(DLBCL)和滤泡性淋巴瘤(FL)中,但也扩展到许多其他癌症中,包括对各种治疗方法产生耐药性的独特作用,这使得 BCL6 抑制剂成为高度需求的药物。